pharmaphorum December 31, 2025
One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong Kong, raising HKD 2.28 billion (around $293 million).
The US and Hong Kong-based company has listed on the HKEX in Hong Kong’s biggest IPO of the year, which was massively oversubscribed, and also the first for an AI-driven biotech on the exchange. It was backed by a long list of investors that included the likes of US pharma group Eli Lilly and Chinese tech giant Tencent.
The IPO – which has gone through after earlier attempts were filed and subsequently dropped – comes after several private funding rounds and takes the total raised by the company well above the $1 billion...
Today's Sponsors
Today's Sponsor